Advertisement
Screener

Summit Therapeutics Inc. (SMMT) Foreign Currency Transaction Gain (Loss), Unrealized

2.4 / 5 stars · 33/68 Roast Me

Summit Therapeutics Inc. Foreign Currency Transaction Gain (Loss), Unrealized

Summit Therapeutics Inc. (SMMT) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$220.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-07-23

  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was -$30.00K, a 112.55% decline year-over-year.
  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$190.00K, a 184.82% decline year-over-year.
  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was -$94.00K, a 154.97% decline year-over-year.
  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was -$49.00K.
  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for fiscal 2025 was $320.00K.
  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for fiscal 2024 was -$229.00K, a 128.20% decline from fiscal 2023.
  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for fiscal 2023 was $812.00K.
  • Summit Therapeutics Inc. foreign currency transaction gain (loss), unrealized for fiscal 2022 was -$2.62M.
Period endForeign Currency Transaction Gain (Loss), Unrealized 3 monthForeign Currency Transaction Gain (Loss), Unrealized 6 monthForeign Currency Transaction Gain (Loss), Unrealized 6 month as first filedForeign Currency Transaction Gain (Loss), Unrealized 9 monthForeign Currency Transaction Gain (Loss), Unrealized 11 monthForeign Currency Transaction Gain (Loss), Unrealized 12 monthForeign Currency Transaction Gain (Loss), Unrealized 12 month as first filed
2026-06-30-$30.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23
-$220.00K
10-Q · filed 2026-07-23
-$314.00K
derived: sum of 3 quarters · filed 2026-07-23
-$363.00K
derived: sum of 4 quarters · filed 2026-07-23
2026-03-31-$190.00K
10-Q · filed 2026-04-30
-$284.00K
derived: sum of 2 quarters · filed 2026-04-30
-$333.00K
derived: sum of 3 quarters · filed 2026-04-30
-$94.00K
derived: sum of 4 quarters · filed 2026-07-23
2025-12-31-$94.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$143.00K
derived: sum of 2 quarters · filed 2026-02-23
$96.00K
derived: sum of 3 quarters · filed 2026-07-23
$320.00K
10-K · filed 2026-02-23
2025-09-30-$49.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20
$190.00K
derived: sum of 2 quarters · filed 2026-07-23
$414.00K
10-Q · filed 2025-10-20
$585.00K
derived: sum of 4 quarters · filed 2026-07-23
2025-06-30$239.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23
$463.00K
10-Q · filed 2026-07-23
$634.00K
derived: sum of 3 quarters · filed 2026-07-23
$119.00K
derived: sum of 4 quarters · filed 2026-07-23
2025-03-31$224.00K
10-Q · filed 2026-04-30
$395.00K
derived: sum of 2 quarters · filed 2026-04-30
-$120.00K
derived: sum of 3 quarters · filed 2026-04-30
$4.00K
derived: sum of 4 quarters · filed 2026-04-30
2024-12-31$171.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$344.00K
derived: sum of 2 quarters · filed 2026-02-23
-$220.00K
derived: sum of 3 quarters · filed 2026-02-23
-$229.00K
10-K · filed 2026-02-23
2024-09-30-$515.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20
-$391.00K
derived: sum of 2 quarters · filed 2025-10-20
-$400.00K
10-Q · filed 2025-10-20
$42.00K
derived: sum of 4 quarters · filed 2026-02-23
2024-06-30$124.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11
$115.00K
10-Q · filed 2025-08-11
$557.00K
derived: sum of 3 quarters · filed 2026-02-23
$63.00K
derived: sum of 4 quarters · filed 2026-02-23
2024-03-31-$9.00K
10-Q · filed 2025-05-01
$433.00K
derived: sum of 2 quarters · filed 2026-02-23
-$61.00K
derived: sum of 3 quarters · filed 2026-02-23
$333.00K
derived: sum of 4 quarters · filed 2026-02-23
2023-12-31$442.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$52.00K
derived: sum of 2 quarters · filed 2026-02-23
$342.00K
derived: sum of 3 quarters · filed 2026-02-23
$812.00K
10-K · filed 2026-02-23
2023-09-30-$494.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
-$100.00K
derived: sum of 2 quarters · filed 2024-10-30
$370.00K
10-Q · filed 2024-10-30
$2.02M
derived: sum of 4 quarters · filed 2025-02-24
2023-06-30$394.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$864.00K
10-Q · filed 2024-08-06
$2.52M
derived: sum of 3 quarters · filed 2025-02-24
$614.00K
derived: sum of 4 quarters · filed 2025-02-24
2023-03-31$470.00K
10-Q · filed 2024-05-01
$2.13M
derived: sum of 2 quarters · filed 2025-02-24
$220.00K
derived: sum of 3 quarters · filed 2025-02-24
-$1.11M
derived: sum of 4 quarters · filed 2025-02-24
2022-12-31$1.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24
-$250.00K
derived: sum of 2 quarters · filed 2025-02-24
-$1.58M
derived: sum of 3 quarters · filed 2025-02-24
-$2.62M
10-K · filed 2025-02-24
-$2.61M
10-K · filed 2023-03-09
2022-09-30-$1.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$3.23M
derived: sum of 2 quarters · filed 2023-11-07
-$4.27M
10-Q · filed 2023-11-07
-$5.24M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$1.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
-$2.37M
10-Q · filed 2023-08-09
-$3.34M
derived: sum of 3 quarters · filed 2023-08-09
-$4.19M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$1.04M
10-Q · filed 2023-05-11
-$2.01M
derived: sum of 2 quarters · filed 2023-05-11
-$2.86M
derived: sum of 3 quarters · filed 2023-05-11
-$3.08M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$972.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
-$1.82M
derived: sum of 2 quarters · filed 2023-03-09
-$2.04M
derived: sum of 3 quarters · filed 2023-03-09
-$326.00K
10-K · filed 2023-03-09
2021-09-30-$849.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$1.07M
derived: sum of 2 quarters · filed 2022-11-09
$646.00K
10-Q · filed 2022-11-09
$884.00K
derived: sum of 4 quarters · filed 2022-12-21
2021-06-30-$224.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$1.50M
10-Q · filed 2022-08-11
$1.73M
derived: sum of 3 quarters · filed 2022-12-21
$1.48M
derived: sum of 4 quarters · filed 2022-12-21
2021-03-31$1.72M
10-Q · filed 2022-05-11
$1.96M
derived: sum of 2 quarters · filed 2022-12-21
$1.71M
derived: sum of 3 quarters · filed 2022-12-21
$2.07M
derived: sum of 4 quarters · filed 2022-12-21
2020-12-31$238.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21
-$14.00K
derived: sum of 2 quarters · filed 2022-12-21
$353.00K
derived: sum of 3 quarters · filed 2022-12-21
$278.00K
10-K/A · filed 2022-12-21
2020-09-30-$252.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$115.00K
derived: sum of 2 quarters · filed 2021-11-15
$40.00K
10-Q · filed 2021-11-15
2020-06-30$367.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$292.00K
10-Q · filed 2021-08-12
$294.00K
8-K · filed 2020-09-29
2020-03-31-$75.00K
10-Q · filed 2021-05-17
2019-12-31-$423.00K
10-K · filed 2021-03-31
2019-09-30-$464.00K
derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16
-$342.00K
10-Q · filed 2020-11-16
2019-06-30$122.00K
8-K · filed 2020-09-29
2019-01-31$0.00
10-K · filed 2021-03-31
2018-01-31$0.00
8-K · filed 2020-09-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52